GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allakos Inc (FRA:37Z) » Definitions » Other Income (Expense)

Allakos (FRA:37Z) Other Income (Expense) : €0.01 Mil (TTM As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Allakos Other Income (Expense)?

Allakos's other income expense for the Allakos's pretax income for the three months ended in Dec. 2023 was €0.05 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2023 was €0.01 Mil.


Allakos Other Income (Expense) Historical Data

The historical data trend for Allakos's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allakos Other Income (Expense) Chart

Allakos Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Income (Expense)
Get a 7-Day Free Trial -0.14 -0.60 1.10 -1.13 0.01

Allakos Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.43 -0.03 - -0.01 0.05

Allakos Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allakos  (FRA:37Z) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.


Allakos (FRA:37Z) Business Description

Traded in Other Exchanges
Address
825 Industrial Road, Suite 500, San Carlos, CA, USA, 94070
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.

Allakos (FRA:37Z) Headlines

No Headlines